NASDAQ:SOPH - Nasdaq - CH1125843347 - Common Stock - Currency: USD
3.18
-0.02 (-0.62%)
The current stock price of SOPH is 3.18 USD. In the past month the price decreased by -8.88%. In the past year, price decreased by -1.85%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
VEEV | VEEVA SYSTEMS INC-CLASS A | 39.85 | 46.10B | ||
DOCS | DOXIMITY INC-CLASS A | 44.68 | 12.48B | ||
WAY | WAYSTAR HOLDING CORP | 43.78 | 6.03B | ||
CERT | CERTARA INC | 22.33 | 1.77B | ||
PHR | PHREESIA INC | N/A | 1.61B | ||
SDGR | SCHRODINGER INC | N/A | 1.41B | ||
HCTI | HEALTHCARE TRIANGLE INC | N/A | 1.37B | ||
GDRX | GOODRX HOLDINGS INC-CLASS A | 9.91 | 1.24B | ||
TDOC | TELADOC HEALTH INC | N/A | 1.23B | ||
LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.08B | ||
EVH | EVOLENT HEALTH INC - A | N/A | 1.06B | ||
CTEV | CLARITEV CORP | N/A | 933.96M |
SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. The company is headquartered in Rolle, Vaud and currently employs 423 full-time employees. The company went IPO on 2021-07-23. The firm offer a cloud-based Software-as-a-Service platform - the SOPHiA DDM, which is data-driven medicine platform enabling insights from disparate, complex datasets to improve diagnosis, treatment, and drug development. The firm has offices in Switzerland, France and the United Kingdom and operates worldwide.
SOPHIA GENETICS SA
La Piece 12
Rolle VAUD CH
CEO: Jurgi Camblong
Employees: 430
Phone: 41216941060
The current stock price of SOPH is 3.18 USD. The price decreased by -0.63% in the last trading session.
The exchange symbol of SOPHIA GENETICS SA is SOPH and it is listed on the Nasdaq exchange.
SOPH stock is listed on the Nasdaq exchange.
11 analysts have analysed SOPH and the average price target is 7.82 USD. This implies a price increase of 145.91% is expected in the next year compared to the current price of 3.18. Check the SOPHIA GENETICS SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SOPHIA GENETICS SA (SOPH) has a market capitalization of 212.52M USD. This makes SOPH a Micro Cap stock.
SOPHIA GENETICS SA (SOPH) currently has 430 employees.
SOPHIA GENETICS SA (SOPH) has a support level at 3.06 and a resistance level at 3.18. Check the full technical report for a detailed analysis of SOPH support and resistance levels.
The Revenue of SOPHIA GENETICS SA (SOPH) is expected to grow by 13.88% in the next year. Check the estimates tab for more information on the SOPH EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SOPH does not pay a dividend.
SOPHIA GENETICS SA (SOPH) will report earnings on 2025-10-13, after the market close.
SOPHIA GENETICS SA (SOPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.44).
The outstanding short interest for SOPHIA GENETICS SA (SOPH) is 0.06% of its float. Check the ownership tab for more information on the SOPH short interest.
ChartMill assigns a technical rating of 2 / 10 to SOPH. When comparing the yearly performance of all stocks, SOPH turns out to be only a medium performer in the overall market: it outperformed 47.4% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to SOPH. SOPH may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months SOPH reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 56.86% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -45.1% | ||
ROE | -77.29% | ||
Debt/Equity | 0.33 |
ChartMill assigns a Buy % Consensus number of 85% to SOPH. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 1.22% and a revenue growth 13.88% for SOPH